Basilea Pharmaceutica International AG Allschwil
- Address
- Hegenheimermattweg 167b
Sponsor Overview
Specializations
Invasive Fungal Infections
The sponsor’s clinical research includes treatment areas for candidemia and invasive candidiasis, with attention to serious bloodstream and deep-seated fungal disease in adults.
- Fosmanogepix
- Systemic Candida infections
- Oral step-down antifungal therapy
These studies focus on difficult-to-treat fungal infections that require effective systemic antifungal options across hospital and specialist care settings.
Invasive Mold Disease
Another major area of interest is invasive mold infections, including disease caused by Aspergillus spp., Fusarium spp., Lomentospora prolificans, and Mucorales fungi.
- Multidrug-resistant molds
- Rare mold pathogens
- Severe pulmonary and disseminated fungal disease
The therapeutic focus extends to infections with limited treatment options, where novel antifungal approaches are needed for adults with complex fungal disease.
Severe Bacterial Pneumonia
The sponsor also supports research in community-acquired bacterial pneumonia, reflecting interest in serious respiratory infections that require inpatient management.
- Lower respiratory tract infection
- Acute bacterial pneumonia
- Hospital-treated respiratory infection
This area aligns with the clinical need for antibacterial therapies in adults with significant respiratory illness.
Gram-Negative Bacterial Infections
Clinical activity also covers severe infections caused by Gram-negative bacteria, a field associated with resistant and high-burden hospital infections.
- Antibacterial treatment
- Resistant Gram-negative pathogens
- Serious systemic infection
These studies support development in antibacterial therapy for infections that remain challenging in acute care settings.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BAL2420 in Healthy Adult Subjects |  The Netherlands | Recruiting |
| An interventional efficacy and safety Phase 3 double-blind 2-arm study to investigate IV followed by oral fosmanogepix compared with IV caspofungin followed by oral fluconazole in adult participants with candidemia and/or invasive candidiasis. |  Austria Belgium Bulgaria France Germany Greece Italy Spain | Recruiting |
| Evaluation of Ceftobiprole and OATP1B Interaction in Patients with Community-Acquired Bacterial Pneumonia | The Netherlands | Not Recruiting |
| Phase 3 Study on the Efficacy and Safety of Fosmanogepix in Adult Patients with Invasive Mold Infections by Aspergillus, Fusarium, and Multidrug-Resistant Molds | Austria Belgium France Germany Greece Italy Spain The Netherlands | Recruiting |
Data & Insights
This sponsor works with 12 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 57 sites across their trial portfolio.
Therapeutic Focus
- 1.Bacterial Infections and Mycoses3 trials180 other sponsors
- 2.Respiratory Tract Diseases1 trial277 other sponsors
Partnered Research Centres
57 centres- Address
- 264 Rue Saint Pierre, 13005 Marseille
- Address
- Piazza Dell'ospedale Maggiore 3, 20162 Milan
- Address
- Ruddershove 10, 8000 Bruges
- Address
- Strada Delle Scotte 14, 53100 Siena
- Address
- Largo Del Pozzo 71, 41124 Modena
- Address
- Via Michele Coppino 26, 12100 Sassari
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Basilea Pharmaceutica International AG Allschwil.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.